GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time scorecard of the Q4 earnings season and new research reports on 16 major ...

The CEO of Globus Medical said the deal will enable the ... down from the $425.2 million in the year-prior due to increased competition in the spinal cord stimulation market.

High competition from other players is an overhang. Per the Zacks analyst, Globus Medical is driving impactful innovations from its prolific R&D pipeline, including the ExcelsiusHub Navigation system.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

CHARLOTTE, N.C. - Dentsply Sirona Inc. (NASDAQ:XRAY), a global leader in dental products and technologies, has announced the ...

Medtronic, and eventually J&J, will give Intuitive competition ... Globus’ Excelsius can make a material difference.” The EPA is expected to finalize new regulations in March that would limit ethylene ...

Whereas, for intercity passenger mobility, a standardized national regulatory framework is essential to replace the fragmented state-specific rules, promoting fair competition and creating ... up with ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.